BioCryst is a short target with about 17% of float, or $259 million, sold short, according to financial analytics firm S3 Partners.
Dynavax Technologies Corp. added another $436 million in market value on Monday on news it had both initiated a mid-stage Covid vaccine study with one partner and that the U. K. had exercised an option to order more inoculations from another Dynavax partner using the company’s adjuvant.
The motivations behind Monday’s 131% rally in Healthier Choices Management Corp. powered by Reddit was unclear as Twitter users said it was an opportunity to send hedge funds “on the run.”
(Updates to add Covid-19 stock plays as well as Healthier Choices trading details)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.
One bright spot was net debt, which was down $1.4 billion from the preceding quarter to $39 billion at year-end.